Sangamo announces UK authorisation of a phase 1/2 clinical trial evaluating the CAR-Treg cell therapy TX200 for kidney transplantation

This article was originally published here

TX200 is being studied for the prevention of immune-mediated rejection following HLA-A2 mismatched kidney transplantation for end-stage renal disease (ESRD). Sangamo expects to open the first clinical sites

The post Sangamo announces UK authorisation of a phase 1/2 clinical trial evaluating the CAR-Treg cell therapy TX200 for kidney transplantation appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply